Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hodgkin Disease × ABVD protocol × Clear all

Phase

Phase 3 10 Phase 2 2 Phase 4 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Hodgkin Disease 1

Interventions

pembrolizumab 1 interferon gamma-1b 1 interferon gamma, Cys(-3), Tyr(-2), Cys(-1)- 1 etoposide phosphate 1 camrelizumab 1 aldesleukin 1 Radiotherapy 1 Peripheral Blood Stem Cell Transplantation 1 Nivolumab 1 Melphalan 1 Lenograstim 1 Interleukin-2 1 Interferon-gamma 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Etoposide 1 Decitabine 1 Cytarabine 1 Cyclosporins 1 Cyclosporine 1 Carmustine 1 Brentuximab Vedotin 1 ABVD protocol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00784537 2018-02-08

HD0801

Fondazione Italiana Linfomi - ETS

Phase 2/3 Completed

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡